Results 21 to 30 of about 4,176,355 (337)
Biomarkers of Mucinous Tumors of the Ovary [PDF]
Disease Markers, 2007 Goli Samimia,b, Laurent Ozbunb, Michael E. Johnsonc, Samuel C. Mokc and Michael J. Birrerb Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD 20892, USA Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA Laboratory of Gynecologic Oncology, Brigham and Women’s ...
Samimi, Goli +4 more
openaire +4 more sources
Frontiers in Immunology, 2021 The environmental and metabolic pressures in the tumor microenvironment (TME) play a key role in molding tumor development by impacting the stromal and immune cell fractions, TME composition and activation.
R. Abou Khouzam +7 more
semanticscholar +1 more source
Imaging biomarkers for evaluating tumor response: RECIST and beyond
Biomarker Research, 2021 Response Evaluation Criteria in Solid Tumors (RECIST) is the gold standard for assessment of treatment response in solid tumors. Morphologic change of tumor size evaluated by RECIST is often correlated with survival length and has been considered as a ...
Ching-Chung Ko, L. Yeh, Y. Kuo, J. Chen
semanticscholar +1 more source
Journal of Extracellular Biology, 2022 Detection of cell‐free circulating tumour DNA (ctDNA) and cancer‐specific extracellular vesicles (EVs) in patient blood have been widely explored as non‐invasive biomarkers for cancer detection and disease follow up.
Mercedes Tkach +7 more
doaj +1 more source
Renal tumor biomarkers (Review)
Experimental and Therapeutic Medicine, 2021 One of the most common types of cancer worldwide (9th most commonly diagnosed) is renal cell carcinoma (RCC). It is more common in developed countries and it usually develops in individuals between 60 and 70 years of age. The earlier the disease is identified, the lower the morbidity.
Ovidiu Gabriel Bratu +11 more
openaire +4 more sources
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]
, 2020 Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin +13 more
core +1 more source
The importance of circulating tumor products as „liquid biopsies” in colorectal cancer [PDF]
, 2018 Liquid biopsies represent an array of plasma analysis tests that are studied to evaluate and identify circulating tumor products, especially circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
Calborean, Veronica +6 more
core +4 more sources
Review of precision cancer medicine: Evolution of the treatment paradigm. [PDF]
, 2020 In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify ...
Fountzilas, Elena +3 more
core +1 more source
Biomarkers in neuroendocrine tumors
Frontiers in Bioscience, 2010 Here, we review the role of clinical biomarkers (tissue and circulating markers) in the management of neuroendocrine tumors. These tumors may originate in different organs, from cells embriologically different but expressing common phenotypic characteristics, such as the immuno-reactivity for markers of neuro endocrine differentiation (defined as "pan ...
BERRETTA M +7 more
openaire +6 more sources
Biomarkers of Tumor Metastasis and Invasiveness
Cancers, 2023 The identification of proteins as new cancer diagnostic and prognostic biomarkers continues to attract considerable attention in the oncology literature, especially in the context of invasion and metastasis activation process [...]
Daniel L. Pouliquen +1 more
openaire +3 more sources